Clemastine Fumarate
hs592 · tavist · Alagyl · agasten · lecasol · piloral · reconin · tavegil
식별자 및 물리적 특성
| CAS No. | 14976-57-9 |
|---|---|
| 분자식 | C25H30ClNO5 |
| 평균 분자량 | 460 g/mol |
| 단동위원소 질량 | 459.1812508 g/mol |
| SMILES | CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1.O=C(O)/C=C/C(=O)O |
| InChIKey | PMGQWSIVQFOFOQ-YKVZVUFRSA-N |
| PubChem CID | 5281069 |
| ChEMBL | CHEMBL1200795 |
| ChEBI | CHEBI:3739 |
| EC No. | 239-055-2 |
| DTXSID | DTXSID6047785 |
화학 및 물리적 성질
| 극성 표면적 | 87.1 |
|---|---|
| 수소 결합 공여자 수 | 2 |
| 수소 결합 수용자 수 | 6 |
| 회전 가능 결합 수 | 8 |
| 무거운 원자 수 | 32 |
| 형식 전하 | 0 |
| 복잡도 | 495 |
| 냄새 | Odorless |
| Color/Form | Colorless to faintly yellow crystalline powder |
| 용해도 | Very slightly soluble in water and sparingly soluble in alcohol.DMSO: 가용성 5mg/mL(투명 용액, 가열) |
| Human Drugs | FDA approved drugs -> Active ingredient |
| 끓는 점 | 154 °C at 0.02 mm Hg154°C (rough estimate) |
| 녹는점 | 177-178 °C158-162°C |
| Other Experimental Properties | 154 °C at 0.02 mm Hg (free base) |
| 밀도 | 1.0247 (rough estimate) |
| 굴절률 | 1.5790 (estimate) |
| 저장 조건 | 2-8°C |
| 물리적 상태 | 가루 |
| 색상 | 흰색에서 베이지색 |
| InChIKey | PMGQWSIVQFOFOQ-YKVZVUFRSA-N |
| SMILES | [C@@](C)(OCC[C@H]1CCCN1C)(C1C=CC=CC=1)C1=CC=C(Cl)C=C1.C(/C(=O)O)=C\C(=O)O |&1:0,5,r| |
화학적 성질
White Solid
안전 및 규제
| GHS 분류 | This chemical does not meet GHS hazard criteria for 66.7% (12 of 18) of all reports.WarningH400 (22.2%): Very toxic to aquatic life [Warning Hazardous to the aquatic environment, acute hazard]P273, P391, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 18 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| FDA 요건 | Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended21 U.S.C. 321-392).The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed drug products, incl clemastine fumarate, approved on the basis of safety and effectiveness by FDA under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. /From the Prescription Drug Product List/ |
| Hazard Classes and Categories | Aquatic Acute 1 (22.2%) |
| 체내 부담 | Following oral administration of 2.68 mg of clemastine fumarate daily for 3 days in one nursing woman, a milk clemastine concentration of about 5-10 ug/ml occurred 20 hours after the last dose of the drug. |
| Milk Concentrations | Following oral administration of 2.68 mg of clemastine fumarate daily for 3 days in one nursing woman, a milk clemastine concentration of about 5-10 ug/ml occurred 20 hours after the last dose of the drug. |
| Human Toxicity Excerpts | Usual therapeutic doses of clemastine interfere with color vision.Drowsiness, irritability, refusal to feed, and high-pitched cry occurred in one breast-fed infant (10 weeks of age) of a women who received 2.68 mg of clemastine fumarate daily for 3 days. |
| Drug Induced Liver Injury | Drug Induced Liver Injury Rank (DILIrank 2.0)Clemastine fumaratevNo-DILI-concernNo matchDOI:10.1016/j.drudis.2016.02.015 |
| Non-Human Toxicity Excerpts |
용도
용도
Clemastine fumarate is a selective histamine H1 receptor antagonist (Ki = 0.26 nM) that also displays high affinity for muscarinic receptors (Ki = 16 nM). It has also recently been identified as a positive allosteric modulator of P2X7 receptor signaling. Clemastine fumarate has long been used to inhibit histamine-induced bronchoconstriction in asthma and airway hyperresponsive studies.
일반 설명
Dextrorotatory clemastine, R,R-2[2[1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1- methylpyrrolidine hydrogen furnarate (1:1) (Tavist), has two chiral centers, each of which has the (R) absolute configuration. A comparison of the activities of the enantiomers indicates that the asymmetric center close to the terminal side chain nitrogen is of lesser importance to antihistaminic activity. This member of the ethanolamine series is characterized by a long duration of action, with an activity that reaches a maximum in 5 to 7 hours and persists for 10 to 12 hours. It is well absorbed when administered orally, and it is excreted primarily in the urine. The side effects are those usually encountered with this series of antihistamines. Clemastine is closely related to chlorphenoxamine, which is used for its central cholinergic-blocking activity. Therefore, it is not surprising that clemastine has significant antimuscarinic activity.